Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

Case weighted power priors for hybrid control analyses with time-to-event data

Adaptive Hybrid Control Design for Comparative Clinical Trials with Historical Control Data

PAM-HC: A Bayesian Nonparametric Construction of Hybrid Control for Randomized Clinical Trials Using External Data

Evaluating hybrid controls methodology in early-phase oncology trials: a simulation study based on the MORPHEUS-UC trial

Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Weighting Based Approaches to Borrowing Historical Controls for Indirect comparison for Time-to-Event Data with a Cure Fraction

Augmenting treatment arms with external data through propensity-score weighted power-priors: an application in expanded access

Enhancing Statistical Validity and Power in Hybrid Controlled Trials: A Randomization Inference Approach with Conformal Selective Borrowing

Matching within a hybrid RCT/RWD: framework on associated causal estimands

A meta-analytic framework to adjust for bias in external control studies

Posterior predictive treatment assignment methods for causal inference in the context of time-varying treatments

A matching design for augmenting a randomized clinical trial with external control

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints

A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials.

A propensity score‐integrated approach for leveraging external data in a randomized controlled trial with time‐to‐event endpoints

Propensity score weighted multi‐source exchangeability models for incorporating external control data in randomized clinical trials

Integrating Randomized Placebo-Controlled Trial Data with External Controls: A Semiparametric Approach with Selective Borrowing

Statistical methods to control for confounders in rare disease settings that use external control

Bayesian Nonparametric Common Atoms Regression for Generating Synthetic Controls in Clinical Trials